Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
Chain Bridge I (CBRG) has announced a definitive agreement to acquire Phytanix Bio, creating a new public company focused on developing next-generation cannabinoid and cannabinoid-like medicines. Phytanix Bio, a preclinical stage pharmaceutical company, holds exclusive intellectual property for such medicines.
The transaction values Phytanix at $58 million and includes the assumption of $17 million in preferred stock and $4.4 million in short-term debt, which will be converted to convertible preferred stock at closing. The merger is expected to complete in Q4 2024, with the combined entity listed on Nasdaq under the ticker 'PHYX'.
Phytanix will be led by experienced founders from GW Pharmaceuticals, with Colin Stott as COO, Dominic Schiller handling legal and IP strategy, and Barrett Evans as CEO. The new company aims to advance its lead product candidates into clinical trials, targeting treatment-resistant facial seizures and Painful Bladder Syndrome.
Chain Bridge I (CBRG) ha annunciato un accordo definitivo per acquisire Phytanix Bio, creando una nuova compagnia pubblica focalizzata sullo sviluppo di medicinali a base di cannabinoidi e simili di nuova generazione. Phytanix Bio, un'azienda farmaceutica in fase preclinica, detiene diritti di proprietà intellettuale esclusivi per tali medicinali.
La transazione valorizza Phytanix a 58 milioni di dollari e include l'assunzione di 17 milioni di dollari in azioni privilegiate e 4,4 milioni di dollari in debito a breve termine, che saranno convertiti in azioni privilegiate convertibili al momento della chiusura. La fusione dovrebbe essere completata nel quarto trimestre del 2024, con l'entità combinata quotata al Nasdaq con il ticker 'PHYX'.
Phytanix sarà guidata da fondatori esperti di GW Pharmaceuticals, con Colin Stott come COO, Dominic Schiller che si occupa della strategia legale e di proprietà intellettuale, e Barrett Evans come CEO. La nuova azienda punta a portare i suoi principali candidati di prodotto in studi clinici, mirando al trattamento di crisi facciali resistenti e della Sindrome della Vescica Dolorosa.
Chain Bridge I (CBRG) ha anunciado un acuerdo definitivo para adquirir Phytanix Bio, creando una nueva compañía pública centrada en el desarrollo de medicamentos de cannabinoides y similares de próxima generación. Phytanix Bio, una empresa farmacéutica en etapa preclínica, posee propiedad intelectual exclusiva para dichos medicamentos.
La transacción valora a Phytanix en 58 millones de dólares e incluye la asunción de 17 millones de dólares en acciones preferentes y 4,4 millones de dólares en deuda a corto plazo, que se convertirá en acciones preferentes convertibles al cierre. Se espera que la fusión se complete en el cuarto trimestre de 2024, y que la entidad combinada se cotice en Nasdaq bajo el símbolo 'PHYX'.
Phytanix será liderada por fundadores con experiencia de GW Pharmaceuticals, con Colin Stott como COO, Dominic Schiller encargándose de la estrategia legal y de propiedad intelectual, y Barrett Evans como CEO. La nueva empresa tiene como objetivo avanzar sus principales candidatos de producto a ensayos clínicos, enfocándose en las crisis faciales resistentes al tratamiento y el síndrome de vejiga dolorosa.
체인 브리지 I (CBRG)가 피타닉스 바이오를 인수하기 위한 최종 계약을 발표하며 차세대 칸나비노이드 및 유사 칸나비노이드 의약품 개발에 초점을 맞춘 새로운 공개 회사를 설립하게 되었습니다. 피타닉스 바이오는 전임상 단계의 제약 회사로, 이러한 의약품에 대한 독점적인 지적 재산권을 보유하고 있습니다.
이번 거래는 피타닉스의 가치를 5천8백만 달러로 평가하며, 1천7백만 달러의 우선주와 440만 달러의 단기 부채 인수를 포함합니다. 이 부채는 계약 체결 시 전환 가능한 우선주로 전환될 예정입니다. 합병은 2024년 4분기에 완료될 것으로 예상되며, 통합 회사는 'PHYX'라는 티커로 나스닥에 상장될 것입니다.
피타닉스는 GW 제약의 경험이 풍부한 창립자들에 의해 이끌어지며, Colin Stott가 COO, Dominic Schiller가 법률 및 지적 재산 전략을 담당하고, Barrett Evans가 CEO로 활동하게 됩니다. 새로운 회사는 치료 저항성 안면 발작 및 통증성 방광 증후군 치료를 목표로 주요 제품 후보를 임상 시험으로 진전시키는 것을 목표로 합니다.
Chain Bridge I (CBRG) a annoncé un accord définitif pour acquérir Phytanix Bio, créant ainsi une nouvelle société cotée en bourse axée sur le développement de médicaments cannabinoïdes et similaires de nouvelle génération. Phytanix Bio, une entreprise pharmaceutique en phase préclinique, détient des droits de propriété intellectuelle exclusifs pour ces médicaments.
La transaction valorise Phytanix à 58 millions de dollars et inclut l'assumption de 17 millions de dollars en actions privilégiées et 4,4 millions de dollars de dettes à court terme, qui seront converties en actions privilégiées convertibles lors de la clôture. La fusion devrait être finalisée au quatrième trimestre de 2024, l'entité combinée étant cotée sur le Nasdaq sous le symbole 'PHYX'.
Phytanix sera dirigée par des fondateurs expérimentés de GW Pharmaceuticals, avec Colin Stott en tant que COO, Dominic Schiller en charge de la stratégie légale et de la propriété intellectuelle, et Barrett Evans en tant que CEO. La nouvelle société vise à faire progresser ses principaux candidats produits vers des essais cliniques, ciblant les crises faciales résistantes au traitement et le syndrome de la vessie douloureuse.
Chain Bridge I (CBRG) hat eine endgültige Vereinbarung zur Übernahme von Phytanix Bio bekannt gegeben und thereby ein neues öffentliches Unternehmen gegründet, das sich auf die Entwicklung der nächsten Generation von Cannabinoid- und cannabinoidähnlichen Arzneimitteln konzentriert. Phytanix Bio, ein Unternehmen in der präklinischen Phase, besitzt exklusive geistige Eigentumsrechte an solchen Arzneimitteln.
Die Transaktion bewertet Phytanix mit 58 Millionen Dollar und umfasst die Übernahme von 17 Millionen Dollar an Vorzugsaktien und 4,4 Millionen Dollar an kurzfristigen Schulden, die bei Abschluss in wandelbare Vorzugsaktien umgewandelt werden. Die Fusion wird voraussichtlich im vierten Quartal 2024 abgeschlossen, wobei das kombinierte Unternehmen unter dem Ticker 'PHYX' an der Nasdaq gelistet wird.
Phytanix wird von erfahrenen Gründern von GW Pharmaceuticals geleitet, wobei Colin Stott COO, Dominic Schiller für die rechtliche und geistige Eigentumsstrategie verantwortlich ist und Barrett Evans als CEO fungiert. Das neue Unternehmen hat sich zum Ziel gesetzt, seine führenden Produktkandidaten in klinische Studien voranzubringen, die auf behandlungsresistente Gesichtsanfälle und das schmerzhafte Blasensyndrom abzielen.
- Phytanix Bio valued at $58 million, indicating strong market confidence.
- Assumption of $17 million in preferred stock and $4.4 million in short-term debt to be converted to convertible preferred stock, showing favorable financing terms.
- Combined company to be listed on Nasdaq, enhancing liquidity and visibility.
- Experienced leadership from GW Pharmaceuticals, boosting credibility and operational expertise.
- Targeting treatment-resistant facial seizures and Painful Bladder Syndrome, addressing unmet medical needs.
- None of the key financial metrics, such as revenue or profit projections, were disclosed.
- $17 million in preferred stock and $4.4 million in short-term debt could strain financials if not managed well.
- Pending shareholder approval and regulatory filings pose a risk of transaction delays.
Insights
The merger between Chain Bridge I and Phytanix Bio marks a significant entry into the rapidly evolving cannabinoid-based pharmaceutical market. This merger is valued at
The company's focus on developing cannabinoid and cannabinoid-like medicines, driven by an experienced team that has previously developed successful products like Sativex® and Epidiolex®, is noteworthy. The management's depth of knowledge and executional experience in securing regulatory approvals could lead to expedited clinical trial phases and eventual market entry.
However, the market response will hinge on the progress of clinical trials and regulatory approvals. Investors should closely monitor these developments, as any significant hurdles could impact the stock's performance. The absence of a minimum cash condition adds an element of risk, which potential investors need to consider carefully.
Phytanix Bio's strategy of utilizing botanically inspired active pharmaceutical ingredients is innovative and could potentially offer new therapeutic options for conditions like treatment-resistant facial seizures and Painful Bladder Syndrome. The preclinical stage offers high upside potential, albeit with considerable risk until clinical efficacy and safety are established.
The leadership team's expertise from GW Pharmaceuticals, particularly their success with cannabinoid-based therapies, adds credibility. Their approach of employing ingredients with known tolerability could accelerate development timelines and reduce adverse event risks, which is critical for regulatory approvals.
Moreover, the alignment with a SPAC like Chain Bridge I could streamline the funding necessary to advance clinical trials. However, investors should be cautious about the inherent uncertainties in preclinical development and the potential for regulatory setbacks.
The legal landscape surrounding cannabinoid-based medicines remains complex and evolving. The merger agreement between Chain Bridge I and Phytanix Bio, which includes a comprehensive intellectual property strategy, showcases a strong legal foundation. The involvement of Nelson Mullins Riley & Scarborough as legal counsel for CBRG and the advisory role of Catherine Basinger Evans, Esq., for Phytanix Bio, ensures that the merger adheres to regulatory requirements.
Phytanix Bio's IP, derived from former GW Pharmaceuticals members, provides a competitive edge by leveraging previously established legal precedents for cannabinoid-based drugs. This IP strategy could potentially safeguard Phytanix Bio from future litigations and enhance its market positioning.
Nevertheless, investors should be aware of potential legal challenges and regulatory hurdles in the cannabinoid pharmaceutical sector. Continuous monitoring of legal developments and regulatory shifts will be essential for assessing the long-term viability of the combined company.
- Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP)
- The transaction reflects a pre-deal valuation of
$58 million for Phytanix Bio plus the assumption of$17 million of preferred stock and$4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close - The business combination is expected to be completed in the fourth quarter of 2024, with the combined company to be listed on Nasdaq Capital Markets under the ticker “PHYX”
NEW YORK and SANTA BARBARA, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, an innovative pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, and Chain Bridge I (Nasdaq: CBRG) (“CBRG”), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”
The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital.
Mr. Evans will serve as CEO of the combined company; Mr. Stott will serve as chief operating officer; and Mr. Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization.
“We are very happy to join forces with CBRG,” said Barrett Evans, CEO of Phytanix. “Phytanix has all the necessary IP, scientific acumen and expertise, as well as management experience to create a new generation of medicines made from cannabinoid and cannabinoid-like molecules for patients with serious unmet medical needs. Our team brings a wealth of firsthand experience and executional knowledge in cannabinoid-based medicine innovation and intellectual property generation, having played crucial roles in the development, and protection of Sativex® and Epidiolex® — key regulatory-approved medicines developed by GW Pharmaceuticals, which was later acquired by Jazz Pharmaceuticals for
Andrew Cohen, CEO, and director of CBRG said, “After an exhaustive search for the right partner, we are delighted to merge with Phytanix Bio. The talented founding team has the depth of experience we were looking for in a still nascent industry of developing life-changing cannabinoid and cannabinoid-like medicines. The team’s initial drug pipeline is well conceived and designed. Having developed regulatory-approved medicines in this sector before, the management group is equipped with the knowledge and expertise to advance a new portfolio of medicines with similar therapeutic capabilities that can address unmet medical needs. Together as Phytanix, we look forward to transforming our promising technologies and IP into world class, regulatory-approved medicines.”
Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines. It focuses on the use of botanically inspired active pharmaceutical ingredients to generate new mechanisms of action and IP across a range of therapeutic areas. The company also aims to reduce potential adverse events and de-risk its overall drug development strategy by focusing on active ingredients which have already demonstrated good tolerability in humans or are closely related to existing drug substances that have been evaluated and show tolerability in large clinical cohorts of people.
The resources of the combined company are expected to provide Phytanix with the necessary capital to advance its lead product candidates into clinical trials, targeting treatment resistant facial seizures and Painful Bladder Syndrome (PBS, formerly known as Interstitial Cystitis (IC)).
Key Transaction Terms
Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to
The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders. Details regarding the composition of the new company’s board, governance, and other relevant information will be disclosed in due course.
Additional information about the transaction will be provided in a Current Report on Form 8-K to be filed by CBRG with the Securities and Exchange Commission (“SEC”) and will be available on the SEC’s website at www.sec.gov. In addition, CBRG intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus, and will file other documents regarding the proposed transaction with the SEC.
Advisors
Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Phytanix Bio was advised by Catherine Basinger Evans, Esq.
About Phytanix Bio
Phytanix Bio is a preclinical stage company, specializing in the development of pharmaceutical medicines made from cannabinoid and cannabinoid-like active ingredients.
About Chain Bridge I
Chain Bridge I (Nasdaq: CBRG) is a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Important Information About the Proposed Merger and Where to Find It
CBRG intends to file with the SEC a registration statement on Form S-4 with a proxy statement containing information about the proposed transaction and the respective businesses of Phytanix Bio and CBRG. CBRG will mail a final prospectus and definitive proxy statement and other relevant documents after the SEC completes its review. CBRG shareholders are urged to read the preliminary prospectus and proxy statement and any amendments thereto and the final prospectus and definitive proxy statement in connection with the solicitation of proxies for the special meeting to be held to approve the proposed transaction, because these documents will contain important information about CBRG, Phytanix Bio, and the proposed transaction. The final prospectus and definitive proxy statement will be mailed to shareholders of CBRG as of a record date to be established for voting on the proposed transaction. Shareholders of CBRG will also be able to obtain a free copy of the proxy statement, as well as other filings containing information about CBRG without charge, at the SEC’s website (www.sec.gov) or by calling 1-800-SEC-0330. Copies of the proxy statement and CBRG other filings with the SEC can also be obtained, without charge, by directing a request to Chain Bridge I, 8 the Green, #17538, Dover Delaware, Attention: CEO.
Participants in Solicitation
Phytanix Bio, CBRG, and their respective directors and executive officers, may be deemed participants in the solicitation of proxies of CBRG’s shareholders in respect of the proposed Business Combination. Information about the directors and executive officers of CBRG and their ownership is set forth in CBRG’s filings with the SEC, including its prospectus relating to its initial public offering, which was filed with the SEC on November 12, 2021. CBRG’s shareholders and other interested persons may obtain more detailed information about the names and interests of the directors and officers of Phytanix Bio and CBRG in the Business Combination will be set forth in CBRG’s filings with the SEC, including the preliminary proxy statement/prospectus and the amendments thereto, the definitive proxy statement/prospectus, and other documents filed with the SEC. These documents can be obtained free of charge from the sources specified above and at the SEC’s website at www.sec.gov.
This press release does not contain all the information that should be considered concerning the Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Before making any voting or investment decision, investors and security holders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Business Combination as they become available because they will contain important information about the proposed Business Combination.
No Offer of Solicitation
This press release will not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Business Combination. This press release will also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are based on current information and expectations, forecasts, and assumptions, and involve a number of judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing CBRG’s or Phytanix Bio’s views as of any subsequent date, and neither CBRG nor Phytanix Bio undertakes any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of CBRG or Phytanix Bio, including the parties ability to complete the Business Combination, the ability of the parties to meet Nasdaq listing requirements, and those other risks set forth in the "Risk Factors" in CBRG’s registration statement on Form S-1 (Registration No. 333-254502), as amended, initially filed with the Commission on March 19, 2021, relating to its initial public offering, annual, quarterly reports and subsequent reports filed with the Commission, as amended from time to time. Copies of such filings are available on the Commission’s website, www.sec.gov. CBRG undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Relations Contact:
Jeff Ramson
jramson@pcgadvisory.com
Media Relations Contact:
Ashlee Vogenthaler
ashlee@pcgadvisory.com
FAQ
What is the value of the Phytanix Bio acquisition by Chain Bridge I?
When is the Chain Bridge I and Phytanix Bio merger expected to complete?
What ticker symbol will the new company trade under?
What are the target conditions for Phytanix Bio's lead product candidates?
Who will lead the new company after the merger?
